21st Century Olympic Doping
By Robin Donovan,
NEO.LIFE
| 07. 22. 2021
Gene editing for performance enhancement may not be the Tokyo cheat, but we asked the experts how far off it might be.
Photo by Serena Repice Lentini on Unsplash
The 2020 Summer Olympics in Tokyo, finally set to kick off this week, have already been upended. After waiting an additional year to qualify, Games athletes will now compete in largely empty venues in an event sparked not by the running of a torch, but a series of closed-door ceremonies. Meanwhile, athletes hope to avoid joining a growing number of competitors who have tested positive for COVID-19 since arriving in Tokyo. Victors will accept gold medals passed to them on trays. Even the specter of cheating has evolved. As technologies like CRISPR leap ahead, a newer threat looms, unsteadily: gene doping.
The World Anti-Doping Agency (WADA) recently barred U.S. track star Shelby Houlihan from the Olympic trials after she tested positive for steroids—which Houlihan blamed on a pig organ meat burrito. The agency also banned sprinter and gold medal favorite Sha’Carri Richardson after she tested positive for THC. In addition to those traditional banned substances, WADA has long banned genetically modified cells and alterations of genome sequences or gene expression “by any...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...